World CNS Summit South Korea 2026

 

Korea is rapidly emerging as a global hub for CNS innovation, with breakthroughs spanning novel modalities, BBB shuttle technologies, and differentiated targets beyond Aβ and tau.

This momentum has attracted growing interest from pharma and investors alike, with major partnerships in 2026 including Fosun & AriBio, Insilico & SK Biopharmaceuticals, and Johnson & Johnson & Prazer Therapeutics, underscoring the significant opportunity to translate promising Korean assets into successful disease-modifying CNS therapies.

Against this backdrop of accelerating investment and innovation, the World CNS Summit South Korea will bring together leading Korean innovators including ABL Bio, AriBio, and ADEL, alongside global industry leaders such as Eli Lilly, Lundbeck, JCR Pharmaceuticals, and Novartis, to exchange insights, forge strategic partnerships, and advance the next generation of disease-modifying therapies for neurological disorders.

 

More Info

---

---